Luteolin
Last reviewed
Luteolin is a plant flavonoid (celery, parsley, artichokes) that stabilizes mast cells more potently than prescription cromolyn sodium in lab studies and crosses the blood-brain barrier to address neuroinflammation. The EDS UK GP Toolkit lists it as an option to consider for MCAS management in hEDS patients. ZebraThrive uses 140 mg daily of a micronized form in the Daily Powder.
At a Glance
Daily Dose
140 mg daily in the Daily Powder, split AM and PM scoops (per v7.8 RFQ)
Key Benefits
How It Works
Think of luteolin as a master mast cell controller that works through multiple locks simultaneously. While cromolyn sodium (Gastrocrom) works through one pathway, luteolin blocks mast cell activation through several.
First, luteolin prevents calcium from entering mast cells-calcium influx is the trigger for degranulation. No calcium surge, no histamine release. Second, it blocks NF-κB, a master switch for inflammatory gene expression. Third, it inhibits protein kinase C (PKC), another pathway that leads to mast cell activation.
What makes luteolin special is that it's the most lipophilic (fat-loving) flavonoid, meaning it crosses the blood-brain barrier effectively. This matters because many patients experience "brain fog" and cognitive symptoms-luteolin can reduce neuroinflammation directly in the brain where it's causing problems. It also induces synthesis of brain-derived neurotrophic factor (BDNF) and other compounds that support nerve health.
What the Research Shows
Head-to-head comparisons show luteolin outperforms the prescription mast cell stabilizer cromolyn sodium.
Cultured human mast cell comparison study
Luteolin more effectively inhibited release of histamine, tryptase, IL-6, IL-8, and TNF-α across 10 different inflammatory markers compared to cromolyn
Luteolin's ability to cross the blood-brain barrier provides unique benefits for cognitive symptoms.
Review of luteolin mechanisms in neuroinflammation
Luteolin reduces microglial activation and IL-6 production in the brain, directly addressing mechanisms underlying brain fog
While no direct MCAS trials exist, clinical studies using luteolin show meaningful effects.
Clinical trial in post-COVID patients
Significant improvements in inflammatory markers and symptoms over 4-6 months using PEA-luteolin combination
Addressing the Triad
Tailored benefits for complex conditions
Luteolin sits near the top of the list for natural mast cell stabilizers, and the mechanism evidence is unusually deep. Beyond what most mast cell options block, luteolin also calms the cytokines (IL-1β, IL-6, TNF) that drive systemic MCAS symptoms, not just histamine. There's good safety data from decades of use in related conditions like allergic rhinitis, and small trials in post-COVID smell loss have shown real benefit. For anyone evaluating mast cell options, luteolin is one of the most well-supported choices on the table.
Luteolin protects connective tissue from the inside. Mast cells release proteases (chymase and tryptase) that turn on the MMPs - the enzymes that break down collagen faster than your body can rebuild it. By calming mast cells, luteolin keeps that destruction cascade from getting started. For the many hEDS patients who also live with MCAS, this is one of the most efficient indirect routes to ECM protection. Less mast cell activity means less collagen degradation means better-protected tissue over time. It's why luteolin earned its spot in the formulation.
Luteolin works upstream of POTS - on the inflammation and mast cell activity that fuel symptoms, particularly in post-viral and post-COVID cases. It crosses the blood-brain barrier well enough to reach the neuroinflammation layer that's increasingly recognized as a POTS driver. A small but compelling RCT in post-COVID smell loss patients showed about 40% improvement on luteolin. Many people in the POTS community also have MCAS in the mix, and luteolin's one of the strongest natural options for both at once. It addresses the layers underneath POTS that standard medications don't reach.
Why We Chose This Form
We use micronized luteolin (≤25 microns). Plain luteolin powder is so poorly water-soluble it can pass through your digestive system without ever entering your bloodstream - plasma levels after standard luteolin doses are often undetectable. Micronization grinds the particles small enough that your gut can actually absorb them. We source generic micronized luteolin meeting that spec rather than paying a branded premium, because the analytical particle-size verification on the Certificate of Analysis is what determines whether the ingredient works in your body. The spec is the product.
Form Comparison
Standard luteolin powder
Only 4-17% bioavailability; most passes through unabsorbed
Generic micronized luteolin (≤25 μm, COA-verified)
Reduced particle size improves absorption to clinical-trial range
Liposomal luteolin
Alternative carrier technology with 2-3x improved absorption; not used here
Co-ultramicronized PEA-luteolin (10:1 ratio)
Co-processed branded combo; we deliver both separately in the powder
Safety & Interactions
Potential Side Effects
Luteolin demonstrates an excellent safety profile in clinical trials up to 26 weeks. Very few adverse effects are reported even in highly reactive MCAS individuals. Unlike quercetin, which causes paradoxical reactions in 10-15% of MCAS patients, luteolin is generally well-tolerated.
Drug Interactions
Luteolin shows minimal CYP450 enzyme interactions. No direct interactions found with beta blockers, antihistamines, fludrocortisone, midodrine, or cromolyn/ketotifen. Theoretical caution with anticoagulants (may enhance effects).
Excipients to Avoid
- Microcrystalline cellulose (wood-derived)
- Magnesium stearate
- FD&C dyes
- Sodium lauryl sulfate
Safe Excipients
- Sunflower lecithin
- Olive pomace oil
- Rice flour
Not recommended during pregnancy or breastfeeding pending more human safety data. Discontinue 2 weeks before surgery. Iron supplements may reduce absorption; space by 2+ hours. Allow 4-6 weeks for full therapeutic effect.
How to Start
| Protocol Step | Suggested Dosage | Key Notes |
|---|---|---|
| Week 1 | 50 mg once daily | Take with fatty meal |
| Week 2 | 50 mg twice daily | Morning and evening with meals |
| Week 3 | 70 mg once daily | Increase single dose |
| Week 4+ | 70 mg twice daily | Target maintenance dose |
"Allow 4-6 weeks for full therapeutic effect. Many patients report initial improvement around week 3-4. Consistent daily dosing is important due to the short half-life."
State of the Evidence
No randomized controlled trials exist specifically in MCAS, hEDS, or POTS populations. Evidence for superior mast cell stabilization comes from in vitro studies comparing luteolin to cromolyn. However, the EDS UK GP Toolkit (Royal College of General Practitioners) lists luteolin as an option to consider for MCAS management in hEDS patients. Additionally, luteolin CANNOT achieve MMP inhibition at oral doses-its value lies exclusively in mast cell stabilization, not collagen protection.
- [1]Luteolin more effective than cromolyn sodium at inhibiting mast cell activationPMID: 38588651
Tsilioni I & Theoharides TC (2024)
- [2]Long-COVID syndrome-associated brain fog and chemofog: Luteolin to the rescuePMID: 33847020
Theoharides TC et al. (2021)
- [3]Ultramicronized PEA and Luteolin Supplement Combined with Olfactory TrainingPMID: 35086448
Di Stadio A et al. (2022)
- [4]Beneficial Effects of Co-Ultramicronized Palmitoylethanolamide/Luteolin in a Mouse Model of AutismPMID: 27611916
Bertolino B et al. (2017)
Common Questions
Written by Ken Chapman, Founder of ZebraThrive. Reviewed and last updated .